Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,039Revenue (TTM) $M159Net Margin (%)11.4Altman Z-Score10.2
Enterprise Value $M1,000EPS (TTM) $0.3Operating Margin %12.3Piotroski F-Score4
P/E(ttm)65.7Beneish M-Score-1.9Pre-tax Margin (%)12.0Higher ROA y-yN
Price/Book8.110-y EBITDA Growth Rate %--Quick Ratio1.5Cash flow > EarningsY
Price/Sales6.85-y EBITDA Growth Rate %--Current Ratio1.7Lower Leverage y-yY
Price/Free Cash Flow41.2y-y EBITDA Growth Rate %-50.5ROA % (ttm)10.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)16.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M49.4ROIC % (ttm)31.1Gross Margin Increase y-yN

Gurus Latest Trades with SUPN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SUPNRobert Bruce 2016-03-31 Reduce-0.12%$10.13 - $15.65
($13.02)
$ 21.0362%Reduce -11.78%224,581
SUPNJoel Greenblatt 2016-03-31 Reduce$10.13 - $15.65
($13.02)
$ 21.0362%Reduce -48.08%17,552
SUPNRobert Bruce 2015-12-31 Reduce-0.57%$12.78 - $18.86
($15.48)
$ 21.0336%Reduce -35.48%254,581
SUPNJoel Greenblatt 2015-12-31 Reduce$12.78 - $18.86
($15.48)
$ 21.0336%Reduce -13.63%33,808
SUPNRobert Bruce 2015-09-30 Reduce-1.5%$13.62 - $21.26
($18.58)
$ 21.0313%Reduce -43.19%394,581
SUPNJoel Greenblatt 2015-09-30 Reduce-0.01%$13.62 - $21.26
($18.58)
$ 21.0313%Reduce -55.66%39,142
SUPNGeorge Soros 2015-06-30 Sold Out -0.01%$12.09 - $18.37
($14.2)
$ 21.0348%Sold Out0
SUPNJoel Greenblatt 2015-06-30 Add0.01%$12.09 - $18.37
($14.2)
$ 21.0348%Add 111.74%88,267
SUPNGeorge Soros 2015-03-31 Buy 0.01%$8.18 - $12.09
($9.45)
$ 21.03123%New holding107,308
SUPNJoel Greenblatt 2015-03-31 Buy $8.18 - $12.09
($9.45)
$ 21.03123%New holding41,686
SUPNRobert Bruce 2014-12-31 Add0.68%$7.49 - $9.49
($8.4)
$ 21.03150%Add 73.65%694,581
SUPNRobert Bruce 2014-09-30 Add0.73%$7.99 - $11.13
($8.98)
$ 21.03134%Add 300.00%400,000
SUPNRobert Bruce 2014-06-30 Buy 0.25%$7.32 - $10.85
($8.88)
$ 21.03137%New holding100,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SUPN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SUPN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PATRICK GREGORY SVP, CFO 2016-07-14Sell3,395$22-4.41view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2016-04-11Sell30,762$16.4927.53view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2015-12-09Sell14,238$14.941.14view
BARRETT M JAMESDirector 2015-12-08Sell212,970$14.5644.44view
BARRETT M JAMESDirector 2015-11-25Sell16,179$16.3528.62view
BARRETT M JAMESDirector 2015-11-18Sell93,000$16.6126.61view
BARRETT M JAMESDirector 2015-11-16Sell119,650$16.2429.5view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2015-11-04Sell5,000$19.95.68view
Schwabe Stefan K.F.Executive Vice President R&D 2015-07-28Sell2,350$21.2-0.8view
PATRICK GREGORY SVP, CFO 2015-07-16Sell6,217$205.15view

Quarterly/Annual Reports about SUPN:

News about SUPN:

Articles On GuruFocus.com
Robert Bruce new Buys Feb 16 2015 
Third Quarter Was Robert Bruce's Busiest in 2014 Nov 21 2014 
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 

More From Other Websites
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 20 2016
Supernus to Host Second Quarter 2016 Earnings Conference Call Jul 20 2016
Supernus Pharma downgraded by Piper Jaffray and Northland Capital Jul 18 2016
Supernus Pharmaceuticals Founder and CEO Jack Khattar joins scPharmaceuticals Board of Directors Jul 12 2016
Brexit can’t stop the market from doing what it wanted to all along Jul 05 2016
4 health stocks to watch Jun 30 2016
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 24 2016
Supernus Announces Issuance of Seventh U.S. Patent Protecting Oxtellar XR® Jun 22 2016
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 17 2016
Supernus Provides Update on Trokendi XR® Migraine sNDA and Reiterates Guidance Jun 16 2016
ETF’s with exposure to Supernus Pharmaceuticals, Inc. : June 9, 2016 Jun 09 2016
Supernus Pharmaceuticals, Inc. :SUPN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 Jun 08 2016
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 03 2016
Supernus Announces Issuance of Sixth U.S. Patent Protecting Oxtellar XR® Jun 02 2016
Supernus Announces Issuance of Sixth U.S. Patent Protecting Oxtellar XR® Jun 02 2016
5 stocks to watch May 26 2016
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 25 2016
Supernus to Present at June Jefferies Healthcare Conference May 24 2016
Supernus to Present at June Jefferies Healthcare Conference May 24 2016
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 19 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)